The fixed triple-combination is intended for the treatment of advanced COPD. It contains anti-inflammatory inhaled corticosteroid and two substances from the group of bronchodilators: β-2 sympathomimetic and antimuscarinic bronchodilator. It is available in spray (pMDI) form; the spray releases extra-fine (extra-fine) particles that provide high pulmonary deposition.
